Pharmaceutical industry Study Guide

📖 Core Concepts Pharmaceutical industry – discovers, develops, manufactures, and markets drugs (branded + generic, biologics, total synthesis). Branded vs. generic drugs – branded drugs are protected by patents; generics are not and are sold after patent expiry. Drug approval – FDA (U.S.) must deem a drug safe and effective before marketing; other regions have their own agencies (MHRA, EMA, NICE). Clinical trial phases – I (toxicity), II (pharmacokinetics/dosing), III (efficacy), IV (post‑marketing safety). Orphan drug – targets ≤ 200 000 patients in the U.S.; gets tax breaks, fee waivers, 7‑year exclusivity. Patents – typically 20 years from filing; protect molecule or manufacturing process. --- 📌 Must Remember Key historical milestones: 1885 rabies vaccine (Pasteur/Roux), 1911 arsphenamine (Ehrlich), 1928 penicillin (Fleming), 1954 polio vaccine (Salk), 1960 oral contraceptive (Enovid), 1962 Kefauver‑Harris amendments (efficacy required). FDA approval pathway: IND → Phase I‑IV → NDA → marketing approval. Cost of a new chemical entity: ≈ $1.3 billion (excluding marketing); some estimates $4–$11 billion. First‑line antihypertensives (2018 Cochrane): thiazide diuretics, calcium‑channel blockers, ACE inhibitors, ARBs. Statin breakthrough: 1971 mevastatin (toxic), 1987 lovastatin (Mevacor) → class reduces CHD mortality (4S trial). --- 🔄 Key Processes Drug Discovery Identify/design candidate molecules (traditional natural products → modern pathway‑targeted biotech). Early work usually at universities or CROs. Pre‑clinical Development In vitro assays → animal (in vivo) studies → safety dossier for IND. Clinical Development Phase I: safety & tolerability in healthy volunteers. Phase II: dose‑finding, pharmacokinetics in patients. Phase III: large‑scale efficacy & safety; data for NDA. Phase IV: post‑approval pharmacovigilance. Regulatory Review FDA evaluates NDA → benefit‑risk → marketing approval → listing in Orange Book. --- 🔍 Key Comparisons Branded drug vs. Generic Branded: patented, higher price, marketed under proprietary name. Generic: no patent, bioequivalent, lower price, may be launched early by brand‑owner. Barbiturates vs. Benzodiazepines Barbiturates: high addiction risk, narrow therapeutic window. Benzodiazepines: safer, replaced barbiturates in the 1960s. Phase III vs. Phase IV Phase III: pre‑approval, confirm efficacy in target population. Phase IV: post‑approval, detect rare adverse events, real‑world effectiveness. --- ⚠️ Common Misunderstandings “FDA only checks safety” – false; FDA requires both safety and proven efficacy. “Generic drugs are inferior” – false; they must demonstrate bioequivalence to the reference product. “All drugs that win patents are automatically expensive forever” – patents expire (20 yr); after that generics enter the market, dramatically reducing price. --- 🧠 Mental Models / Intuition “From bench to bedside” pipeline – think of a ladder: Discovery → Pre‑clinical → Clinical (I‑IV) → Approval → Post‑market. Each rung must be cleared before the next. Patent clock vs. market exclusivity – the 20‑year patent starts at filing, not at launch; effective market exclusivity is often only 10 years after accounting for development time. --- 🚩 Exceptions & Edge Cases Orphan drug designation – grants 7‑year exclusivity even if patent expires earlier. Accelerated/Adaptive approval pathways – can shorten review for drugs treating serious or rare conditions (not detailed in outline but noted as a critique/possible reform). Compulsory licensing (Doha Declaration) – allows governments to bypass patents in public‑health emergencies. --- 📍 When to Use Which Choosing antihypertensive class – start with thiazide diuretic, CCB, ACE‑I, or ARB; consider ARB/ACE‑I for diabetic kidney protection. Selecting a development partner – large pharma for end‑to‑end integration; CROs for specific stages (e.g., Phase II trials). Evaluating cost‑effectiveness – use QALY analyses for NHS/NIHR decisions; high‑cost biologics often need demonstrated cost per QALY benefit. --- 👀 Patterns to Recognize Safety → Efficacy → Market pattern in every new drug story (e.g., penicillin → scale‑up in WWII). Regulatory tightening after tragedies – sulfanilamide (1937) → 1938 FD&C Act; thalidomide (1960‑61) → 1962 Kefauver‑Harris amendments. Innovation clusters – early 1900s German dye chemists → anti‑infectives; 1970s fungal metabolites → statins. --- 🗂️ Exam Traps “All FDA‑approved drugs are safe” – ignore Phase IV data; rare adverse events may emerge later. “Patents always last 20 years after approval” – the 20‑year term starts at filing, not at market launch. “Direct‑to‑consumer advertising is allowed worldwide” – only legal in the United States (per outline). “Orphan drugs are always cheap because of incentives” – incentives aid development, but market price can still be high due to exclusivity. ---